Literature DB >> 15208365

25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon.

Giovanna Bises1, Enikö Kállay, Tina Weiland, Friedrich Wrba, Etienne Wenzl, Elisabeth Bonner, Stefan Kriwanek, Peter Obrist, Heide S Cross.   

Abstract

1,25-dihydroxyvitamin D(3) has anti-mitotic, pro-differentiating, and pro-apoptotic activity in tumor cells. We demonstrated that the secosteroid can be synthesized and degraded not only in the kidney but also extrarenally in intestinal cells. Evaluation of 1,25-dihydroxyvitamin D(3)-synthesizing CYP27B1 hydroxylase mRNA (real-time PCR) and protein (immunoblotting, immunofluorescence) showed enhanced expression in high- to medium-differentiated human colon tumors compared with tumor-adjacent normal mucosa or with colon mucosa from non-cancer patients. In high-grade undifferentiated tumor areas expression was lost. Many cells co-expressed CYP27B1 and the vitamin D receptor. We suggest that autocrine/paracrine antimitotic activity of 1,25-dihydroxyvitamin D(3) could prevent intestinal tumor formation and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208365     DOI: 10.1369/jhc.4B6271.2004

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  42 in total

Review 1.  Vitamin D and Gastrointestinal Cancers: A Narrative Review.

Authors:  Hemant Goyal; Abhilash Perisetti; M Rubayat Rahman; Avi Levin; Giuseppe Lippi
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

2.  VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation.

Authors:  Ratchakrit Srikuea; Xiping Zhang; Ok-Kyong Park-Sarge; Karyn A Esser
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-30       Impact factor: 4.249

3.  Hypovitaminosis D as predisposing factor for atrophic type A gastritis: a case-control study and review of the literature on the interaction of Vitamin D with the immune system.

Authors:  Antonio Antico; Renato Tozzoli; Davide Giavarina; Elio Tonutti; Nicola Bizzaro
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

4.  Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer.

Authors:  Genoveva Murillo; Damien Matusiak; Richard V Benya; Rajendra G Mehta
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

5.  Higher serum levels of vitamin D are associated with a reduced risk of diverticulitis.

Authors:  Lillias H Maguire; Mingyang Song; Lisa E Strate; Edward L Giovannucci; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-15       Impact factor: 11.382

6.  Effect of vitamin D receptor knockout on cornea epithelium wound healing and tight junctions.

Authors:  Rodolfo A Elizondo; Zhaohong Yin; Xiaowen Lu; Mitchell A Watsky
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-24       Impact factor: 4.799

7.  Chemoprevention for colorectal neoplasia.

Authors:  Alyssa D Fajardo; Bruce W Robb
Journal:  Clin Colon Rectal Surg       Date:  2008-11

8.  The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis.

Authors:  Henrik C Horváth; Péter Lakatos; János P Kósa; Krisztián Bácsi; Katalin Borka; Giovanna Bises; Thomas Nittke; Pamela A Hershberger; Gábor Speer; Enikö Kállay
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

9.  CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells.

Authors:  Elizabeth T Jacobs; Chad Van Pelt; Ryan E Forster; Wasiq Zaidi; Elizabeth A Hibler; Michael A Galligan; Mark R Haussler; Peter W Jurutka
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

10.  The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells.

Authors:  Eva Untersmayr; Giovanna Bises; Philipp Starkl; Charles L Bevins; Otto Scheiner; George Boltz-Nitulescu; Fritz Wrba; Erika Jensen-Jarolim
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.